Performance analysis of Arbutus Biopharma (ABUS)
Annual Return
Over the past 3 years, ABUS has had an average annual return of +27.76%, outperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, ABUS has had an average annual return of +9.98%, underperforming the benchmark SPY, which returned +12.73% annual.
Over the past 10 years, ABUS has had an average annual return of +0.74%, underperforming the benchmark SPY, which returned +15.04% annual.
Since Aug 3, 2015, ABUS has had an average annual return of -7.39%, underperforming the benchmark SPY, which returned +14.18% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.02% | +47.11% | +30.79% | +7.30% | -40.11% | +9.58% | +27.68% | -27.41% | -24.16% | +106.17% | -44.95% | -57.62% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.15% | +12.84% | -3.42% | -6.67% | +8.58% | +5.25% | -5.82% | -6.02% | |||||
| 2025 | +1.83% | +3.63% | +1.16% | +1.71% | -5.35% | -8.03% | +6.15% | +13.09% | +22.39% | +4.19% | -6.77% | +9.07% | +47.11% |
| 2024 | -5.21% | +18.17% | -7.87% | +5.82% | +23.08% | -8.03% | +21.98% | +2.67% | -0.52% | -0.14% | -10.02% | -5.49% | +30.79% |
| 2023 | +29.20% | -7.64% | +8.99% | -17.19% | -0.79% | -7.63% | -5.62% | -6.48% | -0% | -9.83% | +11.99% | +21.98% | +7.30% |
| 2022 | -27.77% | +13.90% | -6.89% | -21.81% | +4.28% | +11.54% | -14.76% | -3.91% | -13.95% | +22.54% | +0.40% | -0.85% | -40.11% |
| 2021 | +6.48% | -0.81% | -11.20% | +4.23% | -18.46% | +7.09% | -11.23% | +27.52% | +25.07% | -6.07% | -20.58% | +21.56% | +9.58% |
| 2020 | -6.12% | +11.87% | -65.41% | +14.86% | +87.06% | -16.16% | +109.41% | -23.64% | +7.58% | -9.90% | +60.61% | -21.63% | +27.68% |
| 2019 | -3.67% | +18.98% | -18.44% | -24.87% | -32.36% | +14.31% | -14.44% | -23.01% | +11.26% | -6.89% | +17.60% | +66.54% | -27.41% |
| 2018 | +0.98% | +6.86% | -8.25% | +14.01% | +2.62% | +24.79% | +52.06% | -18.01% | +3.84% | -55.13% | +2.82% | -12.14% | -24.16% |
| 2017 | +8.19% | +1.11% | +21.28% | +4.62% | +0% | +5.90% | -4.17% | +21.73% | +47.63% | -8.87% | -0% | -10.61% | +106.17% |
Drawdown analysis of Arbutus Biopharma (ABUS)
The maximum drawdown for the ABUS was -92.95%, occurring on Oct 9, 2019. This drawdown has not yet recovered.
The current ABUS drawdown is -63.40%.
Since Aug 3, 2015 ABUS has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.95% | Aug 2, 2018 | 298 | Oct 9, 2019 | Ongoing | Ongoing | Ongoing |
| -76.67% | Aug 3, 2015 | 356 | Dec 29, 2016 | 384 | Jul 11, 2018 | 740 |
| -8.12% | Jul 13, 2018 | 10 | Jul 27, 2018 | 3 | Aug 1, 2018 | 13 |